SAGE Therapeutics Inc (SAGE) stock has gained 4.20% over the past week and gets a Bearish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With SAGE Stock Today?
SAGE Therapeutics Inc (SAGE) stock has risen 6.49% while the S&P 500 is down -1.05% as of 1:34 PM on Wednesday, May 20. SAGE is higher by $2.28 from the previous closing price of $35.15 on volume of 456,111 shares. Over the past year the S&P 500 has gained 2.91% while SAGE is down -77.09%. SAGE lost -$12.46 per share in the over the last 12 months.
To screen for more stocks like SAGE Therapeutics Inc click here.
More About SAGE Therapeutics Inc
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-547, it is in Phase 3 clinical trials for super-refractory status epilepticus; and the SAGE-217 program which is in Phase 2 clinical trials for post-partum depression, essential tremor, Parkinson's disease and major depressive disorder. The company is also developing several other compounds for treatment that is in the early stage of development.
